NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type mCRC

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print